Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement

Executive Summary

For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.

You may also be interested in...

UK On Cusp Of Value-Based Procurement With NHS Future Operating Model Going Live

The UK's complex system of procuring medical technology for use in the National Health Service is being simplified. A new system will go live on May 8 under the Future Operating Model (FOM), an initiative that prioritizes outcomes-based rationales and allows for gain-sharing, while also targeting annual NHS savings. At this early stage, the device industry and health-care providers are both displaying a mix of optimism and skepticism.

UK Outlook 2018: IVDs Faces Up To Digital, Pathology Consolidation And IVDR Challenges

UK diagnostics manufacturers face major challenges in adapting to the EU IVDR and to the possible changes that Brexit will bring in regulation, trading conditions, costs and access to talent. In addition, the industry will have to factor in a restructuring of pathology networks and future NHS procurement changes, all while transitioning to digital health-care concepts, says IVD industry association chief Doris-Ann Williams.

UK Outlook 2018: All To Play For In Technology Adoption With AAR Set For Take Off

Navigating the UK medtech innovation landscape is a notoriously complicated exercise, so industry is hoping the recently released Accelerated Access Review will have positive outcomes as 2018 unfolds. Andrew Davies, market access director for the Association of British Healthcare Industries,  says a simplified system of market access for medtech would bring benefits across the board.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts